BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 30257515)

  • 21. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
    Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
    Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
    Kasper S; Kisro J; Fuchs M; Müller C; Schulz-Abelius A; Karthaus M; Rafiyan MR; Stein A
    BMC Cancer; 2018 Nov; 18(1):1124. PubMed ID: 30445951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
    Giuliani J; Fiorica F; Ponturo G; Azzurro M; Ruzzenente A; Bonetti A
    J Oncol Pharm Pract; 2021 Jun; 27(4):974-977. PubMed ID: 33541208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
    Fujimoto Y; Nakanishi R; Nukatsuka M; Matsuoka K; Ando K; Wakasa T; Kitao H; Oki E; Maehara Y; Mori M
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1029-1038. PubMed ID: 32322913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer.
    Baba T; Kokuryo T; Yamaguchi J; Yokoyama Y; Uehara K; Ebata T; Nagino M
    Anticancer Res; 2018 Mar; 38(3):1427-1434. PubMed ID: 29491068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays.
    Rothkamm K; Christiansen S; Rieckmann T; Horn M; Frenzel T; Brinker A; Schumacher U; Stein A; Petersen C; Burdak-Rothkamm S
    Cancer Lett; 2020 Nov; 493():179-188. PubMed ID: 32891715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer.
    Nukatsuka M; Fujioka A; Nagase H; Tanaka G; Hayashi H
    Chemotherapy; 2023; 68(2):102-110. PubMed ID: 36623495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
    Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E
    Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study.
    Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M
    JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
    Suzuki N; Nakagawa F; Matsuoka K; Takechi T
    Oncol Rep; 2016 Dec; 36(6):3123-3130. PubMed ID: 27805254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
    Walter T; Hawkins NS; Pollock RF; Colaone F; Shergill S; Ross PJ
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2575-2587. PubMed ID: 32715436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1376-1387. PubMed ID: 32653227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
    Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.
    Mulet N; Matos I; Noguerido A; Martini G; Élez ME; Argilés G; Tabernero J
    Expert Opin Pharmacother; 2018 Apr; 19(6):623-629. PubMed ID: 29537896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada.
    Samawi HH; Brezden-Masley C; Afzal AR; Cheung WY; Dolley A
    Curr Oncol; 2019 Oct; 26(5):319-329. PubMed ID: 31708650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
    Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
    Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
    Chen J; Wang J; Lin H; Peng Y
    Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.